Screener
Medpace Holdings, Inc. MEDP Oncology — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001668397-26-000025
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Therapeutic Area | ||||
| Metabolic | $219,067 | $147,873 | $456,625 | $295,888 |
| Oncology | 209,372 | 188,558 | 410,611 | 359,034 |
| Other | 98,279 | 118,062 | 191,597 | 213,898 |
| Central Nervous System | 82,858 | 61,129 | 163,065 | 116,030 |
| Cardiology | 59,982 | 58,584 | 116,243 | 116,863 |
| AVAI | 37,773 | 29,105 | 75,794 | 60,168 |
| Total revenue | $707,331 | $603,311 | $1,413,935 | $1,161,881 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Medpace Holdings, Inc.'s oncology — total revenue?
- Medpace Holdings, Inc. (MEDP) reported oncology — total revenue of $98.28M in Q2 2026.
- How has Medpace Holdings, Inc.'s oncology — total revenue changed year-over-year?
- Medpace Holdings, Inc.'s oncology — total revenue decreased by 16.8% year-over-year, from $118.06M to $98.28M.
- What is the long-term trend for Medpace Holdings, Inc.'s oncology — total revenue?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s oncology — total revenue has grown at a 11.2% compound annual growth rate (CAGR), from $267.42M to $408.55M.
- What does oncology — total revenue mean?
- This metric measures the total gross income generated by the 'Other' business segment, representing revenue streams that fall outside the company's primary reporting categories. It captures the financial performance of ancillary services, specialized clinical trial support, or secondary geographic markets. Monitoring this metric helps investors understand the diversification of the company's revenue base and the growth trajectory of its non-core service offerings.
Ask your AI about Medpace Holdings, Inc.'s oncology — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude